Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Open-Label Study to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of Multiple Subcutaneous Injections of PolyPEPI1018 Vaccine as an Add-on Immunotherapy to TAS-102 in Late-Stage Metastatic Colorectal Cancer Subjects

NCT05130060 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05130060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05130060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Open-Label Study to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of Multiple Subcutaneous Injections of PolyPEPI1018 Vaccine as an Add-on Immunotherapy to TAS-102 in Late-Stage Metastatic Colorectal Cancer Subjects
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
January 10, 2022
Completion date
June 11, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colon adenocarcinoma, metastatic colorectal adenocarcinoma, metastatic colorectal carcinoma, metastatic microsatellite stable colon carcinoma, metastatic microsatellite stable colorectal carcinoma, metastatic rectal adenocarcinoma, microsatellite stable rectal carcinoma, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8